Boston, MA 06\/13\/2014 (wallstreetpr) \u2013 Amarin Corporation plc (ADR) (NASDAQ:AMRN)<\/b> announced the publication of demonstrative assessment of patient cases that evaluated the efficacy on lipid factors in hyperlipidemic patients who changed their medication from Lovaza\u00ae capsules to Vascepa\u00ae capsules.<\/p>\n
Study Outcomes <\/b><\/p>\n
The biopharmaceutical company engaged with the development and commercialization of therapeutics to enhance cardiovascular health noticed an improvement in patients as they made the switch. Patients who were earlier treated with Lovaza\u00ae capsules, which are essentially a combination of omega fatty acids, made a switch to the Vascepa\u00ae capsules, which is the only unadulterated EPA prescription omega-3 drug. These patients showed improvement in the outcomes in triglyceride levels as well as showed lower levels of low- density lipoprotein cholesterol. The study, which involved 14 patients, reported to demonstrate substantial lowering in the levels of non- high- density lipoprotein cholesterol and total cholesterol in addition to the reduced triglyceride and low-density lipoprotein cholesterol levels.<\/p>\n
Retrospective Review<\/b><\/p>\n
The study authored by Richard S. Castaldo, MD, involved review of a retrospective chart at four medical practice junctures in Western New York. Dr. Castaldo chose 14 patients for his study who initially had high TG levels, that is were diagnosed to have hyperlipidemia. The lipid factors of these patients were measured before and after two or four months of their switch from Lovaza to Vascepa, each of which were administered in doses of 4 gram per day. The subjects were in the age range of 45 and 79 years. After the change of medication, 12 patients showed lowered TG and LDL-C levels while 13 demonstrated decreased levels of\u00a0TC and non-HDL-C. No significant outcome for alterations in high density lipoprotein cholesterol could be obtained because of mixed results among the subjects. The study further established that Vascepa was well tolerated by the patients, so as to be liable for approval by the U.S. Food and Drug Administration.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 06\/13\/2014 (wallstreetpr) \u2013 Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced the publication of demonstrative assessment of patient cases that evaluated the efficacy on lipid […]<\/p>\n","protected":false},"author":32,"featured_media":25676,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3312,3313],"stock_ticker":[],"class_list":["post-25673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-amarin-corporation-plc-adr-nasdaqamrn","tag-nasdaqamrn","entry"],"acf":[],"yoast_head":"\n